The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...
A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along ...
The request comes amid continuing uncertainty over federal funding, with research and thousands of jobs on the line.
By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...
Q3 2025 Earnings Call Transcript November 24, 2025 BioLineRx Ltd. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.41. Operator: Ladies and gentlemen, thank you for standing ...
A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the yearTessera to receive $150 ...
Since an investor revolt early this year at Air Products and Chemicals, the new leadership at the industrial gas giant has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback